908 Devices Inc.

What they do

The company miniaturizes mass spectrometry and optical spectroscopy into handheld devices, including the MX908, ThreatID, ProtectIR, XplorIR, VipIR and NIRLab. Devices are used at the point of need to identify unknown and invisible materials, including fentanyl and illicit drugs, toxic carcinogens and hazardous bulk materials. Since 2014 it has sold more than 3,700 handheld devices to over 700 customers, including domestic and foreign government agencies. It sold its Desktop Portfolio to Repligen on March 4, 2025, and reports that business as discontinued operations.

Revenue drivers

• Handheld device product sales — Product revenue from handheld Mass Spec and optical spectroscopy devices is the largest revenue source and was the primary driver of second quarter 2026 revenue growth, led by VipIR and the addition of NIRLab.
• VipIR FTIR — Newest FTIR product; the company surpassed its 100th unit shipped since launch and shipped more than 35 VipIR devices in the second quarter of 2026, including 18 units to a major South Asia law enforcement agency.
• NIRLab — Added through the NIRLAB SA acquisition closed in the second quarter of 2026; the company is introducing it to the U.S. market and says it engaged hundreds of prospects across more than 30 agencies in the first 60 days since deal close.
• Recurring revenue — Recurring revenue was $4.9 million, or 31% of total revenues, in the second quarter of 2026, alongside an installed base of 4,101 devices.

Recent performance

Second quarter 2026 revenue was $16.1 million, up 23% year over year, driven by VipIR product revenue and the addition of NIRLab. GAAP gross margin was 52% and adjusted gross margin was 57%, an 85-basis point improvement in adjusted gross margin versus the prior-year quarter. Net loss from continuing operations was $11.9 million and Adjusted EBITDA loss was $1.9 million, a reduction of more than 50% year over year. The installed base grew 23% year over year to 4,101 devices, with 198 devices placed in the quarter. The company ended the quarter with $101.5 million in cash, cash equivalents and marketable securities and no debt outstanding.

Strategy

The company is focused on growing sales of its handheld devices in U.S. and international markets and scaling manufacturing. It is expanding its product line, most recently introducing NIRLab to the U.S. market through the same commercial channel, and continues research and development to develop new products and enhance existing ones. Management highlights momentum with U.S. state and local customers, who represented more than half of revenue in the second quarter. The company also completed the sale of its Desktop Portfolio in March 2025 to concentrate on handheld point-of-need analysis.

Risks

• History of losses — The company has incurred significant operating losses since inception and had an accumulated deficit of $247.2 million as of June 30, 2026, and cannot be certain it will achieve or sustain profitability.
• Public sector dependence — A significant portion of the business depends on sales to the public sector, including U.S. government agencies, where programs are subject to budgetary constraints, political considerations and uncertain future funding.
• Macroeconomic sensitivity — Uncertain global economic conditions, including inflation, tariffs, higher interest rates and geopolitical conflicts, could reduce customer spending and demand for the company's products.
• Competition and technology change — The company faces intense competition from large established laboratory instrument manufacturers and new entrants, and must keep developing new products and enhancements to remain competitive.

Outlook

Management raised the low end of full year 2026 revenue guidance to $68.0 million to $70.0 million, from $67.0 million to $70.0 million previously, representing 21% to 25% growth over 2025 revenue. The company cites a $6 million ProtectIR order from a corrections agency in the Asia-Pacific region secured after quarter end as supporting its second-half revenue outlook. It also points to a robust pipeline of opportunities, particularly among U.S. state and local customers and the newly introduced NIRLab product.